Table 1 Participant characteristics
| Â | Â | Whole study group | Fibromyalgia classification | |
|---|---|---|---|---|
| Â | Â | Median (IQR) or % | Yes | No |
N | Â | 50 | 24 | 26 |
Female | Â | 76% | 75% | 77% |
Age |  | 60 (54–69) | 58 (54–66) | 63 (54–70) |
Current smoker | Â | 21% | 26% | 17% |
Analgesia | Any | 69% | 71% | 65% |
| Â | Paracetamol | 63% | 71% | 54% |
| Â | NSAID | 16% | 17% | 15% |
| Â | Opiate | 37% | 38% | 35% |
DMARD | Methotrexate | 59% | 50% | 65% |
| Â | Sulfasalazine | 22% | 15% | 25% |
| Â | Other nonbiologic DMARD | 36% | 40% | 30% |
| Â | Combination nonbiologic DMARD | 24% | 29% | 15% |
Biologic therapy | Â | 12% | 8% | 16% |
Combination therapy | 31% | 33% | 27% | |
Glucocorticosteroid | Â | 20% | 15% | 21% |
Pressure pain threshold | Â | Â | Â | |
|  | Knee | 173 (119–287) | 133 (58–181)** | 239 (169–470) |
|  | Tibia | 140 (98–246) | 108 (61–167)** | 187 (122–337) |
|  | Sternum | 155 (85–211) | 111 (70–175)** | 179 (149–256) |